- Home
- KODK vs RGNX Comparison
KODK vs RGNX Comparison
Compare KODK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KODK
- RGNX
- Stock Information
- Founded
- KODK 1880
- RGNX 2008
- Country
- KODK United States
- RGNX United States
- Employees
- KODK N/A
- RGNX N/A
- Industry
- KODK Business Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KODK Consumer Discretionary
- RGNX Health Care
- Exchange
- KODK Nasdaq
- RGNX Nasdaq
- Market Cap
- KODK 385.4M
- RGNX 459.1M
- IPO Year
- KODK N/A
- RGNX 2015
- Fundamental
- Price
- KODK $5.18
- RGNX $9.18
- Analyst Decision
- KODK
- RGNX Strong Buy
- Analyst Count
- KODK 0
- RGNX 12
- Target Price
- KODK N/A
- RGNX $36.36
- AVG Volume (30 Days)
- KODK 888.5K
- RGNX 886.8K
- Earning Date
- KODK 11-12-2024
- RGNX 11-06-2024
- Dividend Yield
- KODK N/A
- RGNX N/A
- EPS Growth
- KODK 0.52
- RGNX N/A
- EPS
- KODK 0.71
- RGNX N/A
- Revenue
- KODK $1,052,000,000.00
- RGNX $84,327,000.00
- Revenue This Year
- KODK N/A
- RGNX $7.91
- Revenue Next Year
- KODK N/A
- RGNX $214.75
- P/E Ratio
- KODK $7.75
- RGNX N/A
- Revenue Growth
- KODK N/A
- RGNX N/A
- 52 Week Low
- KODK $3.33
- RGNX $8.54
- 52 Week High
- KODK $6.18
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- KODK 53.71
- RGNX 43.02
- Support Level
- KODK $4.26
- RGNX $8.87
- Resistance Level
- KODK $5.65
- RGNX $12.11
- Average True Range (ATR)
- KODK 0.38
- RGNX 0.96
- MACD
- KODK 0.02
- RGNX -0.05
- Stochastic Oscillator
- KODK 65.83
- RGNX 17.17
About KODK Eastman Kodak Company Common New
Eastman Kodak Co is a United States-based company. The company operates via several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.